Valuation : Processa Pharmaceuticals, Inc.

Market Cap 5.95M 5.11M 4.79M 4.38M 8.26M 567M 8.3M 56.72M 21.98M 286M 22.34M 21.86M 948M P/E 2024
-0.23x
P/E 2025 -0.28x
Enterprise Value 413K 354K 333K 304K 573K 39.39M 576K 3.94M 1.53M 19.87M 1.55M 1.52M 65.81M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.18%
Yield 2024 *
-
Yield 2025 -

Last Transcript : Processa Pharmaceuticals, Inc.

1 day-2.29%
1 week-0.93%
Current month-0.93%
1 month-18.08%
3 months-14.80%
6 months-4.48%
Current year-26.04%
1 week 2
Extreme 2
2.28
1 month 1.8
Extreme 1.8
3.11
Current year 1.67
Extreme 1.6701
3.8
1 year 1.67
Extreme 1.6701
14.24
3 years 1.67
Extreme 1.6701
450
5 years 1.67
Extreme 1.6701
4,495.35
10 years 1.67
Extreme 1.6701
125,195.11
Manager TitleAgeSince
Chief Executive Officer 52 2023-08-07
Investor Relations Contact 60 2011-03-28
Chief Administrative Officer 61 2017-10-03
Director TitleAgeSince
Chairman 73 2011-03-28
Chairman 60 2022-08-15
Director/Board Member 56 2020-02-12
Date Insider Type Main position Quantity % Market Cap.
8/8/26 Fiscal year

Chief Executive Officer

3,200 0.1156%
7/26/26 Other

Chief Financial Officer

11,883 0.4293%
7/26/26 Other

Chief Executive Officer

9,384 0.3390%
Change 5-day change 1-year change 3-year change Capi.($)
-2.29%-0.93%-61.90%-98.63% 5.95M
+3.31%-3.70%+61.03%+103.64% 70.42B
+0.53%+2.01%+48.62%+92.29% 65.4B
-1.31%-0.50%+7.41%-4.29% 28.28B
-0.49%+1.73%+59.01%+11.60% 26.57B
+0.40%-4.80%-5.89%+469.55% 27.16B
+0.05%+1.12%+36.42%-17.68% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.77%-1.59%+13.19%+543.56% 15.87B
-1.09%+3.14%+46.32%+155.12% 13.9B
Average +0.10%+0.95%+47.36%+167.55% 28.83B
Weighted average by Cap. +0.88%+0.72%+56.30%+157.36%

Financials

2024 2025
Net sales - -
Net income -11.85M -10.17M -9.55M -8.72M -16.46M -1.13B -16.53M -113M -43.78M -570M -44.49M -43.53M -1.89B -13.56M -11.64M -10.93M -9.98M -18.83M -1.29B -18.93M -129M -50.11M -653M -50.93M -49.82M -2.16B
Net Debt -1.12M -959K -901K -822K -1.55M -107M -1.56M -10.66M -4.13M -53.79M -4.2M -4.11M -178M -5.54M -4.75M -4.46M -4.07M -7.69M -528M -7.73M -52.79M -20.46M -266M -20.79M -20.34M -882M
Logo Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.
Employees
12
Date Price Change Volume
26-08-26 US$2.130 -2.29% 21,969
26-08-25 US$2.180 +0.46% 56,215
26-08-24 US$2.170 +4.33% 30,510
26-08-21 US$2.080 -3.03% 75,971
26-08-20 US$2.145 -0.23% 27,537

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PCSA Stock